Get the Stockscreener App
41.53
2.19%
0.89
Terns Pharmaceuticals Inc stock is traded at $41.53, with a volume of 2.61M.
It is up +2.19% in the last 24 hours and up +57.82% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
See More
Previous Close:
$40.64
Open:
$40.25
24h Volume:
2.61M
Relative Volume:
0.71
Market Cap:
$4.52B
Revenue:
-
Net Income/Loss:
$-95.90M
P/E Ratio:
-31.46
EPS:
-1.32
Net Cash Flow:
$-79.09M
1W Performance:
-3.24%
1M Performance:
+57.82%
6M Performance:
+1,029%
1Y Performance:
+600.34%
1-Day Range:
$40.12
$42.80
1-Week Range:
$39.15
$43.40
52-Week Range:
$1.865
$48.26
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
41.53 | 4.42B | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.21 | 116.79B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.17 | 81.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.70 | 53.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
845.95 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.77 | 37.48B | 447.02M | -1.18B | -906.14M | -6.1812 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-03-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Resumed | H.C. Wainwright | Neutral |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
Terns Pharmaceuticals proposes $400M equity offering - MSN
Terns Pharmaceuticals (TERN) climbs 53% on stellar leukemia treatment trial - MSN
Pharmaceutical Stocks To Follow TodayDecember 10th - MarketBeat
Jim Cramer highlights massive gains for Terns Pharmaceuticals shareholders - MSN
Terns Pharmaceuticals (TERN) price target increased by 75.91% to 54.63 - MSN
Terns Pharmaceuticals Earnings Notes - Trefis
Terns Pharmaceuticals (TERN) Price Target Increased by 75.91% to 54.63 - Nasdaq
Will Terns Pharmaceuticals Inc. stock gain from government policies2025 Bull vs Bear & Weekly High Potential Alerts - moha.gov.vn
How Terns Pharmaceuticals Inc. stock performs in weak economyEarnings Performance Report & High Conviction Trade Alerts - Улправда
Is Terns Pharmaceuticals Inc. stock attractive for long term wealth buildingJobs Report & Target Return Focused Stock Picks - Улправда
Jim Cramer Highlights Massive Gains for Terns Pharmaceuticals Shareholders - Finviz
Terns Pharmaceuticals unveils promising phase 1 trial data - MSN
Insider Trends: How Terns Pharmaceuticals Inc. stock performs in weak economyJuly 2025 Volume & Free Expert Approved Momentum Trade Ideas - ulpravda.ru
Is Terns Pharmaceuticals Inc. stock a contrarian buy2025 Price Momentum & Free High Accuracy Swing Entry Alerts - ulpravda.ru
Terns Pharmaceuticals (TERN) Stock Today (Dec. 18, 2025): Why Shares Are Sliding After the Rally, and What Analysts Forecast Next - ts2.tech
Jim Cramer Was Asked About These 11 Stocks - Insider Monkey
Operating cash flow per share of Terns Pharmaceuticals, Inc. – GETTEX:430 - TradingView — Track All Markets
Terns Pharmaceuticals (TERN) Stock Today: Latest News, Analyst Forecasts, and What to Watch (December 16, 2025) - ts2.tech
Terns Pharmaceuticals (TERN): Valuation Check After Strong CARDINAL Trial Data for CML Candidate TERN-701 - simplywall.st
Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid LeukemiaSlideshow (NASDAQ:TERN) 2025-12-15 - Seeking Alpha
Terns CEO Amy Burroughs talks cancer drug trial win - CNBC
Biotech ETF SBIO Hovers Near Peak on Rally - ETF Database
Terns Pharmaceuticals raises $747.5 million in upsized offering - Traders Union
Terns Pharmaceuticals (TERN) Climbs 53% on Stellar Leukemia Treatment Trial - Finviz
10 Stocks Delivering Explosive 18-190% Gains - Insider Monkey
Terns Pharmaceuticals (TERN) Price Target Increased by 65.68% to 26.75 - MSN
Why Terns Pharmaceuticals (TERN) Is Up 73.6% After Upsized Equity Raise On Strong TERN-701 Data - Sahm
Terns Pharma (TERN) Stock Analysis Report | Financials & Insights - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
Terns Pharmaceutical prices stock at $40 per share - MSN
Citizens Maintains Terns Pharmaceuticals (TERN) Market Outperform Recommendation - MSN
Terns Pharmaceuticals raises $747.5 million in public offering - Investing.com
Terns Pharmaceuticals raises $747.5 million in public offering By Investing.com - Investing.com Australia
Terns Pharmaceuticals price target raised to $58 from $28 at Oppenheimer - MSN
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Terns Pharmaceuticals stock jumps after new leukemia drug data show strong patient responses - MSN
Terns Pharmaceuticals announces proposed offering of $400M of stock - MSN
Citizens Analyst Raises Price Target for Terns Pharma (TERN) to $57.00 | TERN Stock News - GuruFocus
Terns Pharmaceuticals, Inc. Announces Upsized Public Offering - TradingView — Track All Markets
Terns Pharmaceuticals stock price target raised to $57 from $35 at Citizens - Investing.com Canada
Terns Pharmaceuticals Stock Surge: Analyzing the Leap - StocksToTrade
Terns Pharmaceuticals price target raised to $60 from $20 at HC Wainwright - MSN
Jefferies raises Terns Pharmaceuticals stock price target to $70 on CML data - Investing.com Canada
Terns Pharmaceuticals Stock Soars After Leukemia Drug Delivers Big Early Responses In Tough-To-Treat Patients - Stocktwits
Terns Pharmaceuticals Stock Soars Amid Promising Drug Trial - TipRanks
TERN Upsizes Stock Offering to $502M - GuruFocus
Terns Pharmaceuticals (TERN) Announces Upsized Public Offering - GuruFocus
Why Terns Pharmaceuticals (TERN) Is Up 54.9% After Upsized $650 Million Equity Raise Following TERN-701 Data - Yahoo Finance
Terns Pharmaceuticals Prices Upsized $650 Million Common Stock Offering - marketscreener.com
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):